Key Takeaways:
IMPACT Therapeutics licensed senaparib to Pharmanovia for up to EUR423.5 million, expanding the ovarian cancer drug's reach to 66 countries.
The exclusive agreement grants Pharmanovia rights to manufacture, develop and commercialize senaparib as a maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer, the company said in a filing.
The deal covers Europe, the Middle East and North Africa, Australia and New Zealand. IMPACT is eligible for upfront, regulatory and commercialization milestone payments totaling up to EUR423.5 million, plus tiered royalties on net product sales reaching the mid-twenties percentage range. Senaparib, a PARP1/2 inhibitor, is already approved and reimbursed in China and listed on the National Reimbursement Drug List.
Shares of the Hong Kong-listed company rose as much as 14.93 percent to HKD13.5 before trading at HKD12.93, up 12.24 percent, with turnover of 205,800 shares worth HKD2.65 million. The European Medicines Agency accepted the marketing authorization application for senaparib as first-line maintenance therapy for advanced ovarian cancer in August 2025, with a decision expected in the second half of 2026.
The partnership marks IMPACT's first major step to commercialize its lead drug outside China. Pharmanovia's specialist infrastructure is expected to speed patient access to senaparib once approved and support IMPACT's broader global oncology strategy, the company said.
The most recent analyst rating on IMPACT Therapeutics stock is a Hold with a HK$37.60 price target, according to TipRanks data. The company has a market capitalization of about HK$3.09 billion.
Senaparib enters a competitive PARP inhibitor field that includes AstraZeneca's Lynparza and GlaxoSmithKline's Zejula, both approved for ovarian cancer maintenance therapy. Approval in China and the pending European review give senaparib a foothold in two of the largest oncology markets, while the Pharmanovia deal extends its reach across Europe, the Middle East, North Africa, Australia and New Zealand.
The deal gives IMPACT a potential EUR423.5 million in milestone payments plus ongoing royalties, a substantial revenue stream for a company with a HK$3.09 billion market cap. Investors will watch the EMA decision on senaparib, expected in the second half of 2026, as the next major event for the stock.
This article is for informational purposes only and does not constitute investment advice.
